메뉴 건너뛰기




Volumn 12, Issue 11, 2013, Pages 1059-1067

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): A randomised, double-blind, phase 3 trial

Author keywords

[No Author keywords available]

Indexed keywords

DEXPRAMIPEXOLE; PLACEBO; RILUZOLE;

EID: 84885388013     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70221-7     Document Type: Article
Times cited : (207)

References (36)
  • 1
    • 84930899257 scopus 로고    scopus 로고
    • National Institute of Neurological Disorders and Stroke, National Insitutes of HealthNational Insitutes of Health, (accessed April 15, 2013).
    • Amyotrophic lateral sclerosis (ALS) fact sheet National Institute of Neurological Disorders and Stroke, National Insitutes of HealthNational Insitutes of Health, (accessed April 15, 2013). http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/detail_ALS.htm.
    • Amyotrophic lateral sclerosis (ALS) fact sheet
  • 2
    • 0035978743 scopus 로고    scopus 로고
    • Amyotrophic lateral sclerosis
    • Rowland LP, Schneider NA Amyotrophic lateral sclerosis. N Engl J Med 2001, 344:1688-1700.
    • (2001) N Engl J Med , vol.344 , pp. 1688-1700
    • Rowland, L.P.1    Schneider, N.A.2
  • 3
    • 33645867989 scopus 로고    scopus 로고
    • Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies
    • Bruijn LI, Cudkowicz M Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies. Expert Rev Neurother 2006, 6:417-428.
    • (2006) Expert Rev Neurother , vol.6 , pp. 417-428
    • Bruijn, L.I.1    Cudkowicz, M.2
  • 4
    • 38348998584 scopus 로고    scopus 로고
    • Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications
    • Cozzolino M, Ferri A, Carri MT Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid Redox Signal 2008, 10:405-443.
    • (2008) Antioxid Redox Signal , vol.10 , pp. 405-443
    • Cozzolino, M.1    Ferri, A.2    Carri, M.T.3
  • 5
    • 84856905668 scopus 로고    scopus 로고
    • Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis
    • Morren JA, Galvez-Jimenez N Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. Expert Opin Investig Drugs 2012, 21:297-320.
    • (2012) Expert Opin Investig Drugs , vol.21 , pp. 297-320
    • Morren, J.A.1    Galvez-Jimenez, N.2
  • 6
    • 0028097839 scopus 로고
    • A controlled trial of riluzole in amyotrophic lateral sclerosis
    • ALS/Riluzole Study Group
    • Bensimon G, Lacomblez L, Meininger V A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994, 330:585-591. ALS/Riluzole Study Group.
    • (1994) N Engl J Med , vol.330 , pp. 585-591
    • Bensimon, G.1    Lacomblez, L.2    Meininger, V.3
  • 7
    • 0029977337 scopus 로고    scopus 로고
    • Dose-ranging study of riluzole in amyotrophic lateral sclerosis
    • Amyotrophic Lateral Sclerosis/Riluzole Study Group II
    • Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996, 347:1425-1431. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
    • (1996) Lancet , vol.347 , pp. 1425-1431
    • Lacomblez, L.1    Bensimon, G.2    Leigh, P.N.3    Guillet, P.4    Meininger, V.5
  • 8
    • 84861941975 scopus 로고    scopus 로고
    • Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
    • CD001447.
    • Miller RG, Mitchell JD, Moore DH Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012, 3. CD001447.
    • (2012) Cochrane Database Syst Rev , vol.3
    • Miller, R.G.1    Mitchell, J.D.2    Moore, D.H.3
  • 9
    • 0019845220 scopus 로고
    • The ultrastructure of intramuscular nerves in amyotrophic lateral sclerosis
    • Atsumi T The ultrastructure of intramuscular nerves in amyotrophic lateral sclerosis. Acta Neuropathol 1981, 55:193-198.
    • (1981) Acta Neuropathol , vol.55 , pp. 193-198
    • Atsumi, T.1
  • 10
    • 0029812897 scopus 로고    scopus 로고
    • Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis
    • Sasaki S, Iwata M Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 1996, 47:535-540.
    • (1996) Neurology , vol.47 , pp. 535-540
    • Sasaki, S.1    Iwata, M.2
  • 11
    • 0030026832 scopus 로고    scopus 로고
    • Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis
    • Siklós L, Engelhardt J, Harati Y, Smith RG, Joó F, Appel SH Ultrastructural evidence for altered calcium in motor nerve terminals in amyotropic lateral sclerosis. Ann Neurol 1996, 39:203-216.
    • (1996) Ann Neurol , vol.39 , pp. 203-216
    • Siklós, L.1    Engelhardt, J.2    Harati, Y.3    Smith, R.G.4    Joó, F.5    Appel, S.H.6
  • 12
    • 33750347347 scopus 로고    scopus 로고
    • Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases
    • Lin MT, Beal MF Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
    • (2006) Nature , vol.443 , pp. 787-795
    • Lin, M.T.1    Beal, M.F.2
  • 13
    • 71549121668 scopus 로고    scopus 로고
    • The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start?
    • Lee J, Boo JH, Ryu H The failure of mitochondria leads to neurodegeneration: do mitochondria need a jump start?. Adv Drug Deliv Rev 2009, 61:1316-1323.
    • (2009) Adv Drug Deliv Rev , vol.61 , pp. 1316-1323
    • Lee, J.1    Boo, J.H.2    Ryu, H.3
  • 14
    • 71849088759 scopus 로고    scopus 로고
    • Mitochondria: a therapeutic target in neurodegeneration
    • Moreira PI, Zhu X, Wang X, et al. Mitochondria: a therapeutic target in neurodegeneration. Biochim Biophys Acta 2010, 1802:212-220.
    • (2010) Biochim Biophys Acta , vol.1802 , pp. 212-220
    • Moreira, P.I.1    Zhu, X.2    Wang, X.3
  • 15
    • 79952758621 scopus 로고    scopus 로고
    • Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis
    • Cheah BC, Kiernan MC Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010, 13:911-920.
    • (2010) IDrugs , vol.13 , pp. 911-920
    • Cheah, B.C.1    Kiernan, M.C.2
  • 16
    • 84862793575 scopus 로고    scopus 로고
    • Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency
    • Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res 2012, 1446:1-11.
    • (2012) Brain Res , vol.1446 , pp. 1-11
    • Alavian, K.N.1    Dworetzky, S.I.2    Bonanni, L.3
  • 17
    • 29244439896 scopus 로고    scopus 로고
    • Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]
    • Danzeisen R, Schwalenstoecker B, Gillardon F, et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 2006, 316:189-199.
    • (2006) J Pharmacol Exp Ther , vol.316 , pp. 189-199
    • Danzeisen, R.1    Schwalenstoecker, B.2    Gillardon, F.3
  • 18
    • 84856101199 scopus 로고    scopus 로고
    • The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis
    • Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011, 17:1652-1656.
    • (2011) Nat Med , vol.17 , pp. 1652-1656
    • Cudkowicz, M.1    Bozik, M.E.2    Ingersoll, E.W.3
  • 19
    • 84875744026 scopus 로고    scopus 로고
    • The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials
    • Berry JD, Miller R, Moore DH, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14:162-168.
    • (2013) Amyotroph Lateral Scler Frontotemporal Degener , vol.14 , pp. 162-168
    • Berry, J.D.1    Miller, R.2    Moore, D.H.3
  • 20
    • 0033564460 scopus 로고    scopus 로고
    • Combining mortality and longitudinal measures in clinical trials
    • Finkelstein DM, Schoenfeld DA Combining mortality and longitudinal measures in clinical trials. Stat Med 1999, 18:1341-1354.
    • (1999) Stat Med , vol.18 , pp. 1341-1354
    • Finkelstein, D.M.1    Schoenfeld, D.A.2
  • 21
    • 0034574407 scopus 로고    scopus 로고
    • El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
    • World Federation of Neurology Research Group on Motor Neuron Diseases
    • Brooks BR, Miller RG, Swash M, Munsat TL El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000, 1:293-299. World Federation of Neurology Research Group on Motor Neuron Diseases.
    • (2000) Amyotroph Lateral Scler Other Motor Neuron Disord , vol.1 , pp. 293-299
    • Brooks, B.R.1    Miller, R.G.2    Swash, M.3    Munsat, T.L.4
  • 22
    • 78651262763 scopus 로고    scopus 로고
    • Usefulness of the ALSAQ-5 scale in evaluation of quality of life in amyotrophic lateral sclerosis
    • Gołab-Janowska M, Honczarenko K, Stankiewicz J Usefulness of the ALSAQ-5 scale in evaluation of quality of life in amyotrophic lateral sclerosis. Neurol Neurochir Pol 2010, 44:560-566.
    • (2010) Neurol Neurochir Pol , vol.44 , pp. 560-566
    • Gołab-Janowska, M.1    Honczarenko, K.2    Stankiewicz, J.3
  • 23
    • 36148960127 scopus 로고    scopus 로고
    • Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
    • for the Western ALS Study Group
    • Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007, 6:1045-1053. for the Western ALS Study Group.
    • (2007) Lancet Neurol , vol.6 , pp. 1045-1053
    • Gordon, P.H.1    Moore, D.H.2    Miller, R.G.3
  • 24
    • 70449697216 scopus 로고    scopus 로고
    • Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial
    • Meininger V, Drory V, Leigh P, Ludolph A, Robberecht W, Silani V Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009, 10:378-383.
    • (2009) Amyotroph Lateral Scler , vol.10 , pp. 378-383
    • Meininger, V.1    Drory, V.2    Leigh, P.3    Ludolph, A.4    Robberecht, W.5    Silani, V.6
  • 25
    • 79952199408 scopus 로고    scopus 로고
    • Progression in ALS is not linear but is curvilinear
    • Gordon PH, Cheng B, Salachas F, et al. Progression in ALS is not linear but is curvilinear. J Neurol 2010, 257:1713-1717.
    • (2010) J Neurol , vol.257 , pp. 1713-1717
    • Gordon, P.H.1    Cheng, B.2    Salachas, F.3
  • 26
    • 41149124406 scopus 로고    scopus 로고
    • Lithium delays progression of amyotrophic lateral sclerosis
    • Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci 2008, 105:2052-2057.
    • (2008) Proc Natl Acad Sci , vol.105 , pp. 2052-2057
    • Fornai, F.1    Longone, P.2    Cafaro, L.3
  • 27
    • 84859718510 scopus 로고    scopus 로고
    • Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial
    • Verstraete E, Veldink JH, Huisman MH, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry 2012, 83:557-564.
    • (2012) J Neurol Neurosurg Psychiatry , vol.83 , pp. 557-564
    • Verstraete, E.1    Veldink, J.H.2    Huisman, M.H.3
  • 28
    • 84875273042 scopus 로고    scopus 로고
    • Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
    • Morrison KE, Dhariwal S, Hornabrook R, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013, 12:339-345.
    • (2013) Lancet Neurol , vol.12 , pp. 339-345
    • Morrison, K.E.1    Dhariwal, S.2    Hornabrook, R.3
  • 29
    • 77950628380 scopus 로고    scopus 로고
    • Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
    • the Northeast and Canadian Amyotrophic Lateral Sclerosis consortia
    • Aggarwal SP, Zinman L, Simpson E, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:481-488. the Northeast and Canadian Amyotrophic Lateral Sclerosis consortia.
    • (2010) Lancet Neurol , vol.9 , pp. 481-488
    • Aggarwal, S.P.1    Zinman, L.2    Simpson, E.3
  • 30
    • 77952168830 scopus 로고    scopus 로고
    • A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis
    • Pascuzzi RM, Shefner J, Chappell AS, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010, 11:266-271.
    • (2010) Amyotroph Lateral Scler , vol.11 , pp. 266-271
    • Pascuzzi, R.M.1    Shefner, J.2    Chappell, A.S.3
  • 31
    • 79954591299 scopus 로고    scopus 로고
    • Results of a clinical trial of talampanel in patients with ALS
    • Talampanel ALS Study Group
    • Shefner J, Meininger V Results of a clinical trial of talampanel in patients with ALS. Amyotroph Lateral Scler 2011, 11:44-45. Talampanel ALS Study Group.
    • (2011) Amyotroph Lateral Scler , vol.11 , pp. 44-45
    • Shefner, J.1    Meininger, V.2
  • 32
    • 84892469426 scopus 로고    scopus 로고
    • Stage 3 clinical trial of ceftriaxone in subjects with ALS
    • NEALS Consortium, abstr 001.
    • Cudkowicz M, Shefner J Stage 3 clinical trial of ceftriaxone in subjects with ALS. Neurology 2013, 80(suppl 36). NEALS Consortium, abstr 001.
    • (2013) Neurology , vol.80 , Issue.SUPPL. 36
    • Cudkowicz, M.1    Shefner, J.2
  • 33
    • 53049105819 scopus 로고    scopus 로고
    • ALS drug development: reflections from the past and a way forward
    • Aggarwal S, Cudkowicz M ALS drug development: reflections from the past and a way forward. Neurotherapeutics 2008, 5:516-527.
    • (2008) Neurotherapeutics , vol.5 , pp. 516-527
    • Aggarwal, S.1    Cudkowicz, M.2
  • 34
    • 46749128523 scopus 로고    scopus 로고
    • Designing clinical trials in amyotrophic lateral sclerosis
    • Shefner JM Designing clinical trials in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am 2008, 19:495-508.
    • (2008) Phys Med Rehabil Clin N Am , vol.19 , pp. 495-508
    • Shefner, J.M.1
  • 35
    • 77952190999 scopus 로고    scopus 로고
    • Toward more efficient clinical trials for amyotrophic lateral sclerosis
    • Cudkowicz ME, Katz J, Moore DH, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010, 11:259-265.
    • (2010) Amyotroph Lateral Scler , vol.11 , pp. 259-265
    • Cudkowicz, M.E.1    Katz, J.2    Moore, D.H.3
  • 36
    • 84876319986 scopus 로고    scopus 로고
    • Controversies and priorities in amyotrophic lateral sclerosis
    • Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013, 12:310-322.
    • (2013) Lancet Neurol , vol.12 , pp. 310-322
    • Turner, M.R.1    Hardiman, O.2    Benatar, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.